Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (988)	6/6/2003 7:37:34 AM
From: Icebrg	Read Replies (1) \| Respond to of 1139

ICOS Corporation to Manufacture Two Clinical Candidates for Eli Lilly and Company Friday June 6, 7:17 am ET [They have an approved biologics manufacturing facility, but only one biodrug (IC14) under development. Hmmm] BOTHELL, Wash--(BUSINESS WIRE)--June 6, 2003--ICOS Corporation (Nasdaq:ICOS - News) today announced that it has entered into a biologics manufacturing agreement with Eli Lilly and Company. Under the terms of the agreement ICOS will manufacture two clinical candidates that are being developed by Lilly. "We are pleased to work with Lilly, a company who is recognized for their leadership and commitment to biologics development," stated Gary Wilcox, Ph.D., Executive Vice President, Operations of ICOS. "This agreement builds on our business strategy of providing biologics contract manufacturing services to selected customers in addition to supporting our internal and partnered projects." "Lilly has chosen to outsource a portion of its biologics clinical manufacturing," commented Gus Watanabe, M.D., Executive Vice President, Science and Technology, Lilly. "ICOS was selected over other quality facilities because it has the expertise to produce the material to our requirements and within our aggressive timelines." About ICOS biologics manufacturing capabilities: For over ten years, ICOS has conducted process development and cGMP clinical manufacturing to support the pipeline development of ICOS and corporate partners. For the last three years, ICOS has also provided contract manufacturing services for other biotechnology and pharmaceutical companies. The Company has produced multiple novel therapeutic agents for Phase 1 through Phase 3 clinical studies. The ICOS clinical manufacturing facility located in Bothell, Washington houses areas designed for cGMP production and purification of both cell culture and microbial fermentation products and can accommodate microbial fermentation up to 1,600 L and cell culture production up to 3,000 L. The facility is supported by highly experienced Process Development, Manufacturing, QA, QC and Engineering personnel. Additional information on ICOS' process development and cGMP clinical manufacturing is available at www.icosbiologics.com.